Lead
The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP) voted 8–3 on December 5, 2025 to remove the CDC’s long-standing universal recommendation that all newborns receive a hepatitis B vaccine at birth. Under the new guidance ACIP says recommendations should depend on the mother’s hepatitis B testing status; infants born to mothers who are positive or whose status is unknown continue to be vaccinated at birth. For infants whose mothers test negative, ACIP endorses “individual-based decision-making” between parents and health-care providers, and specifies that any first dose skipped at birth should not be given earlier than two months. The change awaits formal sign-off by the CDC acting director, Health and Human Services Deputy Secretary Jim O’Neill.
Key Takeaways
- ACIP voted 8–3 to remove the universal hepatitis B birth-dose recommendation on December 5, 2025, replacing it with a mother-status–based standard.
- If a mother tests negative for hepatitis B surface antigen, parents and clinicians are advised to decide jointly whether to give the newborn the birth dose (“individual-based decision-making”).
- Infants born to mothers who test positive or whose status is unknown remain recommended to receive the hepatitis B vaccine at birth without change.
- New guidance states that newborns who do not receive a birth dose should get their initial hepatitis B vaccine no earlier than two months of age.
- In a separate vote, ACIP approved 6–4 with one abstention that parents of older children should consult clinicians about hepatitis B antibody testing before administering further hepatitis B doses.
- The committee indicated antibody testing, where used to guide additional doses, should meet a threshold and be covered by insurance, though coverage implementation is not yet finalized.
- The ACIP voting language adds a footnote urging consideration of household or frequent-contact risks, including household members with hepatitis B or close contact with persons from high-prevalence regions.
Background
Since the 1990s public-health authorities in the United States have recommended a universal hepatitis B vaccine dose at birth to reduce perinatal and early-life infections. The birth dose has been a central tool because hepatitis B can be transmitted from an infected mother during childbirth, and early infection carries a high risk of chronic liver disease. Over decades, the universal birth-dose strategy contributed to steep declines in perinatal transmission and rising population immunity among children.
Recent debates have questioned whether universal birth dosing remains the optimal approach for all settings, pointing to improved prenatal screening and lower perinatal transmission rates where maternal testing programs are robust. ACIP deliberations weighed data on maternal screening coverage, population-level hepatitis B prevalence, and the balance of rare vaccine-associated events against the protective benefits of immediate neonatal vaccination. Stakeholders include state health departments, pediatricians, obstetric providers, immigrant communities from high-prevalence countries, and insurers.
Main Event
At the ACIP meeting on December 5, 2025, committee members reviewed epidemiological data and deliberated on draft language that ties newborn vaccination to maternal hepatitis B testing results. The 8–3 vote adopted wording that clarifies infants of HBsAg-positive or unknown-status mothers continue to receive the birth dose, while infants of HBsAg-negative mothers fall under “individual-based decision-making.” The voting document explicitly recommended clinicians and parents consider additional household or exposure risks when making decisions.
The committee also addressed the schedule consequences of foregoing the birth dose: the first hepatitis B vaccine for infants who skip the newborn shot should not be administered before two months of age. ACIP members discussed implementation issues, including how hospitals and birthing centers should document maternal status and parental choices at delivery to ensure timely follow-up when a birth dose is deferred.
In a linked vote on older children, ACIP approved 6–4 (one abstention) a motion that parents should consult clinicians about hepatitis B antibody testing before offering additional vaccine doses to children who may already have protective antibodies. The voting language recommended that such testing determine whether an antibody threshold has been achieved and that testing be covered by insurance, although operational details remain to be determined.
Analysis & Implications
The shift from a universal to a mother-status–based recommendation marks a significant policy change with practical and equity implications. In settings with reliable prenatal screening, a targeted approach may reduce unnecessary immediate postnatal vaccination while preserving protection for highest-risk infants. However, universal birth dosing historically served as a safety net for missed or late maternal screening and for populations with barriers to prenatal care; removing that default increases reliance on effective prenatal testing systems and documentation protocols.
Operationally, hospitals, birthing centers and pediatric practices will need updated protocols to record maternal hepatitis B surface antigen (HBsAg) results, communicate decisions to families, and ensure catch-up schedules if the birth dose is deferred. Public-health surveillance systems must also track any shifts in perinatal transmission rates, particularly in communities with higher background prevalence or incomplete prenatal screening coverage.
Insurance coverage and logistics for the recommended antibody testing in older children could be a bottleneck. ACIP’s language calling for insurance coverage is advisory; payers and state Medicaid programs will decide implementation details. Uneven coverage could create disparities if testing is required to avoid unnecessary revaccination but is not accessible or affordable for all families.
Comparison & Data
| Aspect | Prior Guidance (Universal) | New ACIP Guidance |
|---|---|---|
| Birth-dose requirement | All newborns: recommended at birth | Vaccinate at birth if mother HBsAg-positive or status unknown; otherwise parental choice |
| Timing if birth dose skipped | N/A (birth dose recommended) | Initial dose no earlier than 2 months |
| Older-child revaccination | Routine schedule without universal antibody testing | Consider antibody testing before additional doses; testing threshold to guide coverage |
The table highlights the core differences: universal immediate protection at birth versus a stratified approach tied to maternal status, and a delayed minimum timetable when the birth dose is deferred. These changes shift emphasis from a one-size-fits-all protocol to more individualized clinical decisions and system-level tracking.
Reactions & Quotes
Officials and clinicians responded with a mix of support for targeted risk reduction and concern about implementation gaps in prenatal screening and follow-up. Public-health leaders emphasized continuity of care for infants of infected or untested mothers while urging clarity in operational guidance.
“individual-based decision-making”
ACIP voting language (official)
The phrase above summarizes the committee’s prescription for infants of mothers who test negative: parental choice guided by clinicians rather than an automatic birth dose. ACIP included explanatory footnotes advising providers to weigh additional household or exposure risks.
“Parents should talk to their doctor about hepatitis B antibody testing before considering subsequent vaccination for older children.”
ACIP voting language (official)
That second quoted clause reflects the committee’s move to use serologic testing to guide further doses for older children. ACIP also recommended that testing meet an antibody threshold and be covered by insurance, which raises practical questions for payers and clinics.
Unconfirmed
- Whether HHS Deputy Secretary Jim O’Neill has formally signed and posted the amended recommendation at the CDC website remains pending at the time of reporting.
- Specific insurer policies and state Medicaid decisions on covering antibody testing have not been finalized and could vary by jurisdiction.
- The precise implementation timeline and model hospital documentation templates for maternal HBsAg status and parental choice have not been published publicly.
Bottom Line
ACIP’s December 5, 2025 votes mark a substantive change from a universal birth-dose policy to a mother-status–based, individualized approach for hepatitis B vaccination at birth. The immediate clinical effect is limited for infants born to HBsAg-positive or unknown-status mothers, who remain slated for birth-dose vaccination; for other newborns the decision now rests with parents and clinicians.
Key near-term challenges will be ensuring reliable prenatal screening, consistent documentation at delivery, accessible antibody testing where recommended, and clear payer policies so that decisions do not exacerbate disparities. Public-health agencies and clinical systems must monitor perinatal infection rates and follow up on implementation to assess whether the stratified approach preserves the declines in early-life hepatitis B that the universal strategy helped secure.
Sources
- ABC News — media report summarizing ACIP votes and voting language (news outlet).
- CDC ACIP — official advisory committee information and meeting materials (official government).
- CDC — Hepatitis B — official CDC resource on hepatitis B epidemiology and vaccination guidance (official government).